Vatalanib succinate
CAS: 212142-18-2
Rif. 3D-MIA14218
| 10mg | Prezzo su richiesta | ||
| 25mg | Prezzo su richiesta | ||
| 50mg | Prezzo su richiesta | ||
| 100mg | Prezzo su richiesta | ||
| 250mg | Prezzo su richiesta |
Informazioni sul prodotto
- 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-, butanedioate (1:1)
- Butanedioic acid, compd. with N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine (1:1)
- Cgp 79787D
- N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine butanedioate
- N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine butanedioate (1:1)
- Ptk 787
- Ptk 787/Zk 222584
- Ptk 787Zk22258
- Zk 222584
Vatalanib succinate is a small molecule drug that inhibits the activity of the vascular endothelial growth factor receptor (VEGFR). Vatalanib succinate binds to the VEGFR and prevents it from binding to its ligands, such as stem cell factor. It has been shown to inhibit metastatic colorectal cancer in animal models. Vatalanib succinate also has biological effects on other cancer cells, including HL-60 cells and mcf-7 cells. The combination of vatalanib succinate with other compounds, such as colony-stimulating factors or toll-like receptor antagonists, may have synergistic effects.
Proprietà chimiche
Richiesta tecnica su: 3D-MIA14218 Vatalanib succinate
Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.
